Repligen in Chromatography Pact for Downstream Bioprocessing
By

By
Repligen, a life-sciences company focused on bioprocessing technology, has entered into a pact for chromatography with Purolite Life Sciences, a Bala Cynwyd, Pennsylvania-headquartered chemical manufacturing company. Purolite has agreed to…

Capsugel Expands Micro-Dosing and High-Potency Compound Services
By

By
Capsugel, a contract provider of dosage forms and part of Lonza, has expanded its clinical-trial capabilities for micro-dosing and increased development and manufacturing capabilities for specialized drug products using liquid-filled…

Evonik, Lilly Renew API Supply Pact
By

By
Eli Lilly and Company and Evonik Industries have renewed a long-term agreement under which Evonik will supply active pharmaceutical ingredients (APIs) and intermediates for use in key Lilly’s human and…

Amgen, Novartis Expand Alzheimer’s Disease Pact
By

By
Novartis, Amgen, and the Banner Alzheimer’s Institute (BAI) have expanded their collaboration in Alzheimer’s disease to initiate a new clinical trial, the Alzheimer’s Prevention Initiative Generation Study 2. Since 2015, Amgen and Novartis have…

Amgen Buys Out Partner in Kirin-Amgen JV
By

By
Amgen and Kirin Holdings have agreed that Kirin-Amgen, a joint venture between the two companies, will redeem Kirin’s shares in the joint venture for $780 million and, as a result,…

Mallinckrodt To Acquire Ocera Therapeutics
By

By
Mallinckrodt, a specialty pharmaceutical company, has agreed to acquire Ocera Therapeutics, a Redwood City, California-headquartered clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, for $117 million. Ocera’s developmental product,…

Merck KGaA in Lupus Pact
By

By
Merck KGaA and the Lupus Foundation of America, a national voluntary health organization based in Washington, D.C., have agreed to collaborate on The ALPHA Project: Addressing Lupus Pillars for Health…

BI Forms NASH Pact for Liver Disease
By

By
Boehringer Ingelheim and Dicerna Pharmaceuticals, a Watertown, Massachusetts-headquartered biotechnology company, have signed a research collaboration and license agreement to discover and develop GalXC RNAi therapeutics for treating chronic liver diseases.…

Teva Completes $675-Million Divestment of Women’s Health Products
By

By
Teva Pharmaceutical Industries has completed its previously announced $675-million sale of its emergency contraceptive, Plan B One-Step, and its value brands of emergency contraception products to Foundation Consumer Healthcare, a…

Valeant Sells Back Previous $1-Billion Buy of Women’s Healthcare Drug
By

By
Valeant Pharmaceuticals has agreed to divest its women’s healthcare subsidiary, Sprout Pharmaceuticals, to former shareholders of Sprout in exchange for a 6% royalty on global sales of Sprout’s lead drug,…